UB Paderborn / Katalog / Suche / in CDI

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

BMC medical research methodology, 2023-09, Vol.23 (1), p.1-202, Article 202

2023

Link zum Volltext

Verfügbarkeit prüfen

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

Cancer cell, 2003-09, Vol.4 (3), p.181-189

2003

Link zum Volltext

Verfügbarkeit prüfen

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study

European journal of cancer (1990), 2018-02, Vol.90, p.92-101

2018

Link zum Volltext

Verfügbarkeit prüfen

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Cancer, 2024-05

2024

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD4-12-PD4-12

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

European journal of cancer (1990), 2018-10, Vol.102, p.40-48

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P4-P4-08-06

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-13-10

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P2-P2-09-16

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-30

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-01-08-OT1-01-08

2017

Link zum Volltext

Verfügbarkeit prüfen

Outside director compensation policy and the investment opportunity set

Journal of corporate finance (Amsterdam, Netherlands), 2005-09, Vol.11 (4), p.680-715

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-06-07

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S6-S6-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-10-OT1-03-10

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.PD5-02-PD5-02

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P4-P4-14-11

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT2-07-08-OT2-07-08

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-28

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-08-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-14-16

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S3-S3-05

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract S6-02: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S6-S6-02

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.S1-S1-03

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Correction: A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer

Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study

Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

Abstract PD4-12: Clustering of activated proteins of the PI3K and MAPK pathways distinguishes ER+/HER2- primary breast cancer patients with preferential tamoxifen benefit

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04)

Abstract P4-08-06: Phosphorylation of insulin-like growth factor-1 receptor (IGF-1R) is associated with tamoxifen resistance by activating the PI3K/MAPK pathway

Abstract P1-13-10: Adjuvant treatment of HER2+ breast cancer: Should trastuzumab be given sequentially or concurrently with chemotherapy?

Abstract P2-09-16: How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Abstract OT1-01-08: Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Outside director compensation policy and the investment opportunity set

Risk-Adjusted Cancer Screening and Prevention (RiskAP): Complementing Screening for Early Disease Detection by a Learning Screening Based on Risk Factors

Abstract P1-06-07: Characterization of chromosomal instability in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Abstract S6-06: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Abstract OT1-03-10: A phase I followed by a r andomiz e d phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy v ersus capec i tabine in BRCA-1 or -2 mutated Her2 negative ad v anced breast c a ncer as first l ine treatment (REVIVAL study)

Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat?

Abstract P4-14-11: No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Abstract P3-07-28: BRCA1-like profile as predictive biomarker in non myeloablative chemotherapy (GAIN study)

Abstract P6-08-06: Neoadjuvant tamoxifen therapy synchronizes ERα binding and gene expression profiles

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study

Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients

Abstract S6-02: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04)

Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Aktive Filter

Suchergebnisse filtern